CREST
(Placebo controlled high dose Creatine)
The goal of CREST is to determine if high dose Creatine will slow progression of Huntington’s Disease. to study the effects of creatine monohydrate in adults who have clinical features of Huntington’s Disease (HD). CREST-E is designed to measure the effects of creatine monohydrate on the progression of HD in comparison to placebo. CREST-E is designed to determine if creatinine monohydrate is safe and tolerable and to examine its effects on the body. The study is placebo controlled, meaning 50% of patients will receive the study drug, and 50% of the patients will receive placebo, or an inactive pill that looks and tastes like the study drug. The researcher will not know who receives the drug and who receives the placebo. This is a 3 year study of adults patients with symptoms of Huntington’s Disease.
The study will recruit:
- Men/Women age 16 yrs and up
- Adults age 18 yrs and up
- Participants must be psychiatrically stable
- Participants must be on stable doses of all meds for 4 weeks prior to entering study
- Participants cannot have swallowing difficulties
Participants may require minor assistance with functioning in activities of daily living (UHDRS TFC score of 7 or greater)
- Caregiver is not required, but if there is a spouse/caregiver they will be asked to be available by phone to provide information about the participant throughout the study and make sure the
participants are taking study drug as directed.
- For more information, click here
The requirements listed above are not comprehensive. Study subjects must meet all of the individual study protocol criteria and in the opinion of the site study doctor and the sponsor’s medical monitor have the ability to participate in and complete the study.
